Basel

Running trials

• Recruiting

  PULSE Registry: for Patients Receiving Lutetium (177Lu) Vipivotide Tetraxetan

  NCT07484269· Source

• Recruiting

  A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)

  NCT07357727· Phase 3· Source

• Active, not recruiting

  An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)

  NCT07517263· Phase 3· Source

• Recruiting

  A Study to Investigate the Efficacy, Safety and Tolerability of Votoplam in Participants With Huntington's Disease

  NCT07326709· Phase 3· Source

• Active, not recruiting

  Post-authorization Safety Study of Iptacopan in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Using Data From the IPIG PNH Registry

  NCT06903234· Source

• Active, not recruiting

  Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Severe Active GPA or MPA

  NCT06868290· Phase 2· Source

• Recruiting

  Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy

  NCT06780670· Phase 2/3· Source

• Active, not recruiting

  A Clinical Trial to Learn About the Effects of VHB937 in People With Amyotrophic Lateral Sclerosis (ALS)

  NCT06643481· Phase 2· Source

• Recruiting

  Kesimpta Pregnancy and Infant Safety Study Using Real World Data

  NCT06156683· Source

• Active, not recruiting

  A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.

  NCT05739383· Phase 3· Source

• Active, not recruiting

  Study Evaluating LDL-C Change and Adherence to Inclisiran Lipid-lowering Therapy in ASCVD

  NCT05399992· Source

• Active, not recruiting

  Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) (REMODEL-1)

  NCT05147220· Phase 3· Source

• Active, not recruiting

  Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS

  NCT03650114· Phase 3· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Prostate cancer2 recruiting
• Childhood cancers1 recruiting
• Huntington's disease1 recruiting
• Multiple sclerosis1 recruiting
• Myeloproliferative neoplasms1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  Kesimpta® (Ofatumumab) in Swiss Multiple Sclerosis Patients - an Observational Study

  NCT05285904· Source

• Completed

  Survey Among Healthcare Professionals Treating Patients With Metastatic Breast Cancer in Selected European Countries to Evaluate Their Knowledge on Management of Hyperglycemia When Using Alpelisib

  NCT05073120· Source

• Completed

  Survey Among Healthcare Professionals and MS Patients to Assess Their Understanding of RMP Materials

  NCT05301907· Source

• Completed

  Crizanlizumab Pregnancy Outcomes Intensive Monitoring

  NCT07554547· Source

• Completed

  An Open-label Study Evaluating Ofatumumab Treatment Effectiveness and PROs in Subjects With RMS Transitioning From Fumarate-based RMS Approved Therapies or Fingolimod to Ofatumumab

  NCT04353492· Phase 3· Source

• Completed

  Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With CVD

  NCT04023552· Phase 3· Source

• Completed

  Study to Allow Access to Imatinib for Patients Who Are on Imatinib Treatment in a Novartis-sponsored Study and Are Benefiting From the Treatment as Judged by the Investigator

  NCT01742299· Phase 4· Source

• Completed

  The Gilenya Pregnancy Registry

  NCT01285479· Source